These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

811 related items for PubMed ID: 12115394

  • 1. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 2. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 01; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 3. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 4. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ.
    N Engl J Med; 1999 Jan 21; 340(3):190-5. PubMed ID: 9917226
    [Abstract] [Full Text] [Related]

  • 5. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.
    Cancer; 2003 May 01; 97(9):2290-300. PubMed ID: 12712486
    [Abstract] [Full Text] [Related]

  • 6. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.
    Eur J Cancer; 2005 Jun 01; 41(9):1278-85. PubMed ID: 15939263
    [Abstract] [Full Text] [Related]

  • 7. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    J Clin Oncol; 2003 Nov 15; 21(22):4105-11. PubMed ID: 14559891
    [Abstract] [Full Text] [Related]

  • 8. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ.
    J Clin Oncol; 2001 Mar 15; 19(6):1759-67. PubMed ID: 11251007
    [Abstract] [Full Text] [Related]

  • 9. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG, Berglind AM, Andersson H, Boman K, Högberg T, Hallgren M, Schmidt M.
    Cancer; 1998 Sep 01; 83(5):1022-32. PubMed ID: 9731907
    [Abstract] [Full Text] [Related]

  • 10. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 Dec 01; 88(12):1790-6. PubMed ID: 16518975
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM.
    Cancer; 2009 Dec 15; 115(24):5807-16. PubMed ID: 19834961
    [Abstract] [Full Text] [Related]

  • 13. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R.
    Am J Clin Oncol; 1994 Dec 15; 17(6):522-6. PubMed ID: 7977174
    [Abstract] [Full Text] [Related]

  • 14. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ.
    Cancer; 2005 Aug 15; 104(4):864-8. PubMed ID: 15973669
    [Abstract] [Full Text] [Related]

  • 15. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.
    Breast Cancer Res Treat; 2009 Feb 15; 113(3):529-35. PubMed ID: 18327706
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N, Kosmas CH, Vadiaka M, Kontos A, Katsorida M, Dimitrakopoulos A, Zerai A, Koufos CH.
    J Exp Clin Cancer Res; 2001 Mar 15; 20(1):29-34. PubMed ID: 11370826
    [Abstract] [Full Text] [Related]

  • 17. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG, Tyson LB, Clark RA, Gralla RJ.
    Cancer; 1992 Aug 15; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [Abstract] [Full Text] [Related]

  • 18. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S, Banba J, Tomoyasu H, Masaki M.
    Gan To Kagaku Ryoho; 1998 Dec 15; 25(14):2275-81. PubMed ID: 9881085
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research.
    J Clin Oncol; 2004 Feb 15; 22(4):725-9. PubMed ID: 14966097
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 15; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.